Toll Free: 1-888-928-9744

West Nile Virus Infections - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 71 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

West Nile Virus Infections - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'West Nile Virus Infections - Pipeline Review, H2 2016', provides an overview of the West Nile Virus Infections pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for West Nile Virus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for West Nile Virus Infections and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of West Nile Virus Infections
- The report reviews pipeline therapeutics for West Nile Virus Infections by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved West Nile Virus Infections therapeutics and enlists all their major and minor projects
- The report assesses West Nile Virus Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for West Nile Virus Infections

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for West Nile Virus Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding West Nile Virus Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 West Nile Virus Infections Overview 7 Therapeutics Development 8 Pipeline Products for West Nile Virus Infections - Overview 8 Pipeline Products for West Nile Virus Infections - Comparative Analysis 9 West Nile Virus Infections - Therapeutics under Development by Companies 10 West Nile Virus Infections - Therapeutics under Investigation by Universities/Institutes 11 West Nile Virus Infections - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 West Nile Virus Infections - Products under Development by Companies 14 West Nile Virus Infections - Products under Investigation by Universities/Institutes 15 West Nile Virus Infections - Companies Involved in Therapeutics Development 16 CEL-SCI Corporation 16 Hemispherx Biopharma, Inc. 17 Kineta, Inc. 18 Nanotherapeutics, Inc. 19 Plex Pharmaceuticals, Inc. 20 West Nile Virus Infections - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Target 22 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Drug Profiles 30 Alferon LDO - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 BG-323 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 CEL-1000 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 FDX-000 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 HydroVax-001 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 interferon alfa-n3 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 KIN-1148 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 KIN-1400 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Monoclonal Antibody for West Nile Virus Infections - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 rintatolimod - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 RL-15A - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 Small Molecule to Inhibit NS2B-NS3 Protease for Dengue, Zika and West Nile Virus Infection - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 Small Molecules for Viral Infections - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 Small Molecules to Inhibit NS3 Protease for Dengue and West Nile Virus Infections - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 Synthetic Peptide for Dengue Virus and West Nile Virus Infections - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 Tatbeclin-1 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 West Nile virus vaccine - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 West Nile virus vaccine - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 West Nile Virus Infections - Dormant Projects 63 West Nile Virus Infections - Product Development Milestones 66 Featured News & Press Releases 66 Jul 06, 2015: NIH-funded vaccine for West Nile Virus enters human clinical trials 66 May 05, 2014: Alferon N Effective Against MERS Virus In-Vitro 67 Sep 12, 2013: Hemispherx Announces Initial Test Results in Biosecurity/Biodefense Arena 67 Sep 06, 2011: Hemispherx Enters Into Strategic Alliance With Armada Health Care For Alferon N Injection 68 Apr 20, 2010: Kineta Scientist to Present Novel Antiviral Research Findings at International Conference 69 Appendix 70 Methodology 70 Coverage 70 Secondary Research 70 Primary Research 70 Expert Panel Validation 70 Contact Us 70 Disclaimer 71
List of Tables
Number of Products under Development for West Nile Virus Infections, H2 2016 8 Number of Products under Development for West Nile Virus Infections - Comparative Analysis, H2 2016 9 Number of Products under Development by Companies, H2 2016 10 Number of Products under Investigation by Universities/Institutes, H2 2016 11 Comparative Analysis by Clinical Stage Development, H2 2016 12 Comparative Analysis by Early Stage Development, H2 2016 13 Products under Development by Companies, H2 2016 14 Products under Investigation by Universities/Institutes, H2 2016 15 West Nile Virus Infections - Pipeline by CEL-SCI Corporation, H2 2016 16 West Nile Virus Infections - Pipeline by Hemispherx Biopharma, Inc., H2 2016 17 West Nile Virus Infections - Pipeline by Kineta, Inc., H2 2016 18 West Nile Virus Infections - Pipeline by Nanotherapeutics, Inc., H2 2016 19 West Nile Virus Infections - Pipeline by Plex Pharmaceuticals, Inc., H2 2016 20 Assessment by Monotherapy Products, H2 2016 21 Number of Products by Stage and Target, H2 2016 23 Number of Products by Stage and Mechanism of Action, H2 2016 25 Number of Products by Stage and Route of Administration, H2 2016 27 Number of Products by Stage and Molecule Type, H2 2016 29 West Nile Virus Infections - Dormant Projects, H2 2016 63 West Nile Virus Infections - Dormant Projects (Contd..1), H2 2016 64 West Nile Virus Infections - Dormant Projects (Contd..2), H2 2016 65



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify